Back to today’s briefing

Story perspectives

FDA Approves Elevidys Gene Therapy Amid Ongoing Safety Investigations

7/29/2025

24 2

Summary

FDA Approves Gene Therapy

The U.S. FDA has cleared the way for Sarepta Therapeutics' Elevidys gene therapy, previously on hold after the tragic death of an 8-year-old boy was found unrelated to the treatment. Yet, the agency remains vigilant, investigating safety concerns tied to three other deaths associated with Sarepta's therapies this year.

Summary

Sarepta Restructures Amid Scrutiny

Sarepta Therapeutics faces a challenging chapter as it grapples with regulatory scrutiny and financial pressure. The FDA's investigation into Elevidys, tied to patient deaths, has prompted a significant restructuring aimed at saving $400 million each year. Yet, the company's pivot towards siRNA therapies sparks hope for recovery and renewed growth in the fierce biotech arena.

1 of 2

FDA Approves Gene Therapy

The U.S. FDA has cleared the way for Sarepta Therapeutics' Elevidys gene therapy, previously on hold after the tragic death of an 8-year-old boy was found unrelated to the treatment. Yet, the agency remains vigilant, investigating safety concerns tied to three other deaths associated with Sarepta's therapies this year.

1 / 2